News & Views

  • Expert to Strengthen eCOA Offering
    Estelle Haenel

Expert to Strengthen eCOA Offering

Oct 12 2019 Read 614 Times

Clinical trials solutions provider Kayentis has appointed Estelle Haenel, PharmD,PhD as Medical Director, a role that includes facilitating both sites’ and patients’ adoption of eCOA (electronic Clinical Outcome Assessment) solutions as these technologies have matured.

With more than 25 years’ pharma industry experience, including 18 years in clinical science and operations, she will bring to the forefront of the company strategy the perspectives of patients, sites and customers. Improving overall patient engagement in clinical trials, will help pharmas, biotechs and CROs better meet the increasing regulatory requirements for more data and more patient-centric studies. The company’s new generation eCOA platform, Clin’form3, is designed to improve patient engagement, connection with medical devices and wearables, as well as BYOD implementation.
“Kayentis is delighted to welcome Estelle,” said Guillaume Juge, company CEO. “She brings extensive pharma industry experience and high-level skills that will consolidate our clinical knowledge, enhance our focus and reinforce the quality of care we provide to sites and patients. She will make a significant contribution to helping our customers across Europe, North America and Asia

design and implement robust digital trial data collection studies.

Concentrated on phases IIB/III the business is increasingly extending its services towards late phase studies and Real-World Evidence (RWE). It has conducted digital data collection for over 200 clinical trials in 75 countries (9,000 sites and 70,000 patients) employing 90 different languages in a broad range of therapeutic areas.

“Kayentis’ growth has been impressive. This is due to the quality, energy and dedication of its teams,” said Estelle Haenel. “In its positioning as 100% eCOA-focused, it has specially trained staff fully dedicated to preparing, delivering and maintaining eCOA solutions for customers. I have confidence in Kayentis’ high-quality and innovative eCOA solutions to support efficient clinical trials.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia December 2019

December 2019

In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...

View all digital editions


Nano Tech 2020

Jan 29 2020 Tokyo, Japan


Feb 03 2020 Dubai, UAE

Smart Factory Expo (SFE 2020)

Feb 12 2020 Tokyo, Japan

SmartLab Exchange

Feb 17 2020 Berlin, Germany

SIAF Guangzhou

Feb 26 2020 Guanghzou, China

View all events